PCSK9 inhibitors

Innovation Type: Medication

Speciality:

Innovation Origin: Accelerated Access Collaborative (AAC)

For treatment of primary hypercholesterolaemia and mixed dyslipidaemia.

Two cost-effective drugs that significantly lower cholesterol:

This innovation is being supported by the Accelerated Access Collaborative - for more details about the AAC, see the AHSN's dedicated web page, or the AAC's official home page.


For more information, please visit:

< Back to Innovation Finder

Contact us

If you'd like to discuss this Innovation, have an idea or a new Innovation, please get in touch.